KL-P301
KL-P301 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 6, 2026: “Multistrain probiotics ameliorate tau pathology and preserve visuospatial cognition in early cognitive impairment: A double-blind, randomized controlled trial”.
1 paper studies it3 findingsUpdated
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“the probiotic group exhibited a significant reduction in plasma pTau181 levels compared with the placebo group ( p < 0.001).”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Chosun University and 1 more
- Human trial1
Studies in people
1 study gave KL-P301 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases pTau181/p < 0.001 up: Improves cognitive functionp = 0.010 up: Improves visuospatial functionp = 0.036, p = 0.027 | Randomized trial24 weeks | 87 peopleolder adultsOlder adults; early cognitive impairment | medRxiv, Feb 6, 2026 |
What did studies of KL-P301 find?
3Studies of KL-P301 measured 3 outcomes: visuospatial function, cognitive function and pTau181/.
Visuospatial function
upin humans1
1 study
Visuospatial function
upin humans1
KL-P301 improves visuospatial function in humans (early cognitive impairment) (p = 0.036, p = 0.027).
Human trialearly cognitive impairment24 weeksn = 87
Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
KL-P301 improves cognitive function in humans (early cognitive impairment) (p = 0.010).
Human trialearly cognitive impairment24 weeksn = 87
pTau181/
downin humans1
1 study
pTau181/
downin humans1
KL-P301 decreases pTau181/ in humans (early cognitive impairment) (p < 0.001).
Human trialearly cognitive impairment24 weeksn = 87